Pasireotide in Prevention of GI Toxicity

Inclusion Criteria: * 18 years of age or older at the time of study enrollment. * Histologically confirmed diagnosis for which an allogeneic transplant is utilized. * Plan to receive an allogeneic transplant from a 4-6/6 single or dual umbilical cord blood graft, or a 7-8/8 HLA-matched sibling or unrelated donor (High resolution HLA-A, B, C, DRB1). * Meet standard criteria as defined by the institution for a myeloablative allogeneic stem cell transplantation, with myeloablative defined as using conditioning regimens containing: * TBI ≥ 1200 cGy, or * Busulfan ≥ 12.8mg/kg * Patient must have given written informed consent according to FDA guidelines. * Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures. Exclusion Criteria: * Female patients who are pregnant or lactating, or are of childbearing potential (FCBP, defined as all women physiologically capable of becoming pregnant) and not practicing an effective method of contraception/birth control * FCBP must have a current negative serum pregnancy test prior to transplant per institutional practice. * Use of an investigational drug within 1 month prior to dosing. Concurrent enrollment on other clinical research studies that contain an interventional therapy is not permitted while subjects are receiving pasireotide or within 5 half-lives of finishing pasireotide. However, subjects may concurrently enroll in non-interventional studies (e.g. biobanking, mobi…